These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2116256)

  • 1. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
    Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
    Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
    Taburet AM; Devillers A; Thomare P; Fillastre JP; Veyssier P; Singlas E
    Clin Pharmacokinet; 1990 Jul; 19(1):80-8. PubMed ID: 2116257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
    Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
    Stuck AE; Frey FJ; Heizmann P; Brandt R; Weidekamm E
    Antimicrob Agents Chemother; 1989 Mar; 33(3):373-81. PubMed ID: 2499248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
    De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ
    J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
    Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of fleroxacin in man.
    Sörgel F; Seelmann R; Naber K; Metz R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of quinolones in renal insufficiency.
    Fillastre JP; Leroy A; Moulin B; Dhib M; Borsa-Lebas F; Humbert G
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():51-60. PubMed ID: 2124213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered disposition of fleroxacin in patients with cystic fibrosis.
    Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
    Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single and multiple dose pharmacokinetics of fleroxacin.
    Weidekamm E; Portmann R; Partos C; Dell D
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
    Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
    Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
    Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
    Sorgel F; Metz R; Naber K; Seelmann R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of fleroxacin in renal impairment.
    Weidekamm E
    Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis.
    Fillastre JP; Taburet AM; Fialaire A; Etienne I; Bidault R; Singlas E
    Drugs Exp Clin Res; 1993; 19(1):25-32. PubMed ID: 8223137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
    Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A
    Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans.
    Jynge P; Skjetne T; Gribbestad I; Kleinbloesem CH; Hoogkamer HF; Antonsen O; Krane J; Bakøy OE; Furuheim KM; Nilsen OG
    Clin Pharmacol Ther; 1990 Nov; 48(5):481-9. PubMed ID: 2121409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fleroxacin clinical pharmacokinetics.
    Stuck AE; Kim DK; Frey FJ
    Clin Pharmacokinet; 1992 Feb; 22(2):116-31. PubMed ID: 1551289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.
    Singlas E; Taburet AM; Landru I; Albin H; Ryckelinck JP
    Eur J Clin Pharmacol; 1987; 31(5):589-93. PubMed ID: 3830244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.